Difference between revisions of "Radotinib (Supect)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Kinase inhibitors" to "") |
Warner-admin (talk | contribs) m (Text replacement - "[[Chronic myelogenous leukemia" to "[[Chronic myeloid leukemia") |
||
| Line 4: | Line 4: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | *[[Chronic | + | *[[Chronic myeloid leukemia]] |
==Also known as== | ==Also known as== | ||
Revision as of 00:30, 6 September 2022
Not currently approved in the United States.
Mechanism of action
From the NCI Drug Dictionary: a second-generation tyrosine kinase inhibitor of Bcr-Abl fusion protein and the platelet-derived growth factor receptor (PDGFR), with potential antineoplastic activity. Upon administration, radotinib specifically inhibits the Bcr-Abl fusion protein, an abnormal enzyme expressed in Philadelphia chromosome-positive chronic myeloid leukemia (CML) cells. In addition, this agent also inhibits PDGFR thereby blocking PDGFR-mediated signal transduction pathways.
Diseases for which it is used
Also known as
- Code name: IY5511HCl
- Brand name: Supect